Cytomegalovirus clinical trials

Explore recruiting cytomegalovirus clinical trials.

Recruiting cytomegalovirus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cytomegalovirus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized trial of tacrolimus monotherapy compared to standard triple immune suppressive medication in elderly recipients of a kidney transplant to reduce infection-related mortality and improve quality of life; the TACMONO-XL study.

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Finland, Italy, Spain, France, Belgium, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

LUCY-1 - Letermovir/valganciclovir combination versus valganciclovir monotherapy for treatment of cytomegalovirus (CMV) infections in kidney transplant recipients

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicenter randomized two arms study evaluating the efficacy of prophylactic Rituximab in EBV negative kidney transplant recipients on incidence of EBV primary infection and post-transplant lymphoproliferative disorders - REPLY

France

Therapeutic use (Phase IV) EU CTIS Study details

PILOT ANTI-CMV CLINICAL TRIAL: PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN HLA-IDENTICAL FAMILIAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH ADVANCED CELLULAR IMMUNOTHERAPY IN PATIENTS WITHOUT SPECIFIC PHARMACOLOGYCAL PROPHYLAXIS AVAILABLE

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Comparison of the efficacy and safety of valaciclovir in the prevention of transmission and treatment of intrauterine infection in pregnant women with primary cytomegalovirus infection depending on the used drug dose - the first Polish non-commercial non-inferiority clinical trial.

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Cytomegalovirus trials by city

Cytomegalovirus in Toronto Cytomegalovirus in Vancouver Cytomegalovirus in Montreal Cytomegalovirus in Calgary Cytomegalovirus in Edmonton Cytomegalovirus in Ottawa Cytomegalovirus in Winnipeg Cytomegalovirus in Quebec City Cytomegalovirus in Hamilton Cytomegalovirus in Kitchener Cytomegalovirus in London Cytomegalovirus in Halifax Cytomegalovirus in New York Cytomegalovirus in Los Angeles Cytomegalovirus in Chicago Cytomegalovirus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease